Evofem Biosciences, Inc. has announced the completion of a reverse stock split of its common stock at a ratio of 1-for-1,500. This decision, effective November 18, 2026, is intended to enhance the company's stock price and potentially attract more investors. The move comes as part of a broader strategy to stabilize the company's financial standing in the competitive pharmaceutical industry.

The reverse stock split was approved by shareholders during the Annual Meeting held on November 26, 2025. The company determined that this action was in its best interest, allowing it to consolidate its shares while maintaining the same total authorized common stock. As a result, every 1,500 shares of the company's common stock will be converted into one share, without any change in the par value per share.

Founded in 2014 and headquartered in San Diego, California, Evofem Biosciences operates in the pharmaceutical preparations sector (SIC 2834). The company focuses on developing innovative products for women's health, aiming to address unmet medical needs.

According to the recent SEC filing, the reverse stock split was finalized with the filing of a Certificate of Amendment with the Secretary of State of Delaware on November 5, 2026. A subsequent Certificate of Correction was filed on November 17, 2026, to adjust the effective date of the split. Following the split, the company's common stock will trade under the symbol "EVFMD" for a period of twenty business days before reverting to "EVFM."

The filing also indicates that adjustments will be made to stock options, convertible notes, and other equity instruments to reflect the new share structure. Shareholders entitled to fractional shares as a result of the split will receive a cash payment based on the closing trading price prior to the effective date.

This strategic move may not only impact Evofem but could also influence other companies within the pharmaceutical preparations sector as they consider similar measures to improve their stock performance and market appeal.

Looking ahead, the company has not specified any further actions following this filing. The next steps may include monitoring the market's response to the reverse stock split and evaluating its effects on investor interest.